Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2020
Historique:
pubmed: 28 1 2020
medline: 14 5 2021
entrez: 28 1 2020
Statut: ppublish

Résumé

As the Japanese population ages, caring for people with Alzheimer's disease (AD) dementia is becoming a major socioeconomic issue. To determine the contribution of patient and caregiver costs to total societal costs associated with AD dementia. Baseline data was used from the longitudinal, observational GERAS-J study. Using the Mini-Mental State Examination (MMSE) score, patients routinely visiting memory clinics were stratified into three groups based on AD severity. Health care resource utilizationwas recorded using the Resource Utilization in Dementia questionnaire. Total monthly societal costs were estimated using Japan-specific unit costs of services and products (patient direct health care use, patient social care use, and informal caregiving time). Uncertainty around mean costs was estimated using bootstrapping methods. Overall, 553 community-dwelling patients withADdementia (28.3% mild[MMSE21-26], 37.8% moderate[MMSE 15-20], and 34.0% moderately severe/severe [MMSE < 14]) and their caregivers were enrolled. Patient characteristics were: mean age 80.3 years, 72.7% female, and 13.6% living alone. Caregiver characteristics were: mean age 62.1 years, 70.7% female, 78.8% living with patient, 49.0% child of patient, and 39.2% sole caregiver. Total monthly societal costs of AD dementia (Japanese yen) were: 158,454 (mild), 211,301 (moderate), and 294,224 (moderately severe/severe). Informal caregiving costs comprised over 50% of total costs. Baseline results of GERAS-J showed that total monthly societal costs associated with AD dementia increased with AD severity. Caregiver-related costs were the largest cost component. Interventions are needed to decrease informal costs and decrease caregiver burden.

Sections du résumé

BACKGROUND
As the Japanese population ages, caring for people with Alzheimer's disease (AD) dementia is becoming a major socioeconomic issue.
OBJECTIVE
To determine the contribution of patient and caregiver costs to total societal costs associated with AD dementia.
METHODS
Baseline data was used from the longitudinal, observational GERAS-J study. Using the Mini-Mental State Examination (MMSE) score, patients routinely visiting memory clinics were stratified into three groups based on AD severity. Health care resource utilizationwas recorded using the Resource Utilization in Dementia questionnaire. Total monthly societal costs were estimated using Japan-specific unit costs of services and products (patient direct health care use, patient social care use, and informal caregiving time). Uncertainty around mean costs was estimated using bootstrapping methods.
RESULTS
Overall, 553 community-dwelling patients withADdementia (28.3% mild[MMSE21-26], 37.8% moderate[MMSE 15-20], and 34.0% moderately severe/severe [MMSE < 14]) and their caregivers were enrolled. Patient characteristics were: mean age 80.3 years, 72.7% female, and 13.6% living alone. Caregiver characteristics were: mean age 62.1 years, 70.7% female, 78.8% living with patient, 49.0% child of patient, and 39.2% sole caregiver. Total monthly societal costs of AD dementia (Japanese yen) were: 158,454 (mild), 211,301 (moderate), and 294,224 (moderately severe/severe). Informal caregiving costs comprised over 50% of total costs.
CONCLUSION
Baseline results of GERAS-J showed that total monthly societal costs associated with AD dementia increased with AD severity. Caregiver-related costs were the largest cost component. Interventions are needed to decrease informal costs and decrease caregiver burden.

Identifiants

pubmed: 31985460
pii: JAD190811
doi: 10.3233/JAD-190811
pmc: PMC7175940
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-138

Références

Rinsho Shinkeigaku. 2012;52(11):962-4
pubmed: 23196483
Int Psychogeriatr. 2017 Dec;29(12):2081-2093
pubmed: 28720158
Gerontologist. 1980 Dec;20(6):649-55
pubmed: 7203086
J Neurol Sci. 2007 Sep 15;260(1-2):175-82
pubmed: 17553526
Acta Psychiatr Scand. 2011 Nov;124(5):384-95
pubmed: 21838738
BMC Geriatr. 2018 Feb 23;18(1):57
pubmed: 29471784
PLoS One. 2018 Nov 12;13(11):e0206508
pubmed: 30418983
J Prev Alzheimers Dis. 2018;5(1):55-64
pubmed: 29405234
CMAJ. 1998 Sep 8;159(5):457-65
pubmed: 9757169
J Alzheimers Dis. 2013;36(2):385-99
pubmed: 23629588
Curr Alzheimer Res. 2010 Jun;7(4):358-67
pubmed: 19939223
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Qual Life Res. 2006 May;15(4):631-43
pubmed: 16688496
Alzheimers Dement. 2011 May;7(3):318-27
pubmed: 21575872
PLoS One. 2015 Apr 10;10(4):e0123289
pubmed: 25860130
Acta Psychiatr Scand. 2010 Apr;121(4):243-59
pubmed: 19694634
J Neurol Neurosurg Psychiatry. 2005 Dec;76 Suppl 5:v2-7
pubmed: 16291918
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21
pubmed: 9236948
Alzheimers Dement. 2015 Aug;11(8):933-45
pubmed: 25846298
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9
pubmed: 9236950
J Am Geriatr Soc. 2007 Sep;55(9):1458-63
pubmed: 17767690
Acta Psychiatr Scand. 2010 Oct;122(4):319-25
pubmed: 20626720
Innov Clin Neurosci. 2017 Feb 01;14(1-2):22-29
pubmed: 28386518
Gerontologist. 2011 Aug;51(4):425-32
pubmed: 21804114
Am J Psychiatry. 1984 Nov;141(11):1356-64
pubmed: 6496779
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
Int J Integr Care. 2001;1:e28
pubmed: 16896410
Int J Alzheimers Dis. 2012;2012:956354
pubmed: 23091769
J Gerontol B Psychol Sci Soc Sci. 2001 Jul;56(4):S219-28
pubmed: 11445614
Clinicoecon Outcomes Res. 2017 Dec 28;10:13-28
pubmed: 29343976
Int J Qual Health Care. 2019 Apr 1;31(3):231-237
pubmed: 30272131
Alzheimers Dement. 2014 Jul;10(4):468-476.e3
pubmed: 23954026
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Nutr Health Aging. 2010 Oct;14(8):655-63
pubmed: 20922342
J Prev Alzheimers Dis. 2018;5(3):184-187
pubmed: 29972211

Auteurs

Miharu Nakanishi (M)

Mental Health and Nursing Research Team, Mental Health Promotion Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

Ataru Igarashi (A)

Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, and Yokohama City University, Yokohama, Japan.

Kaname Ueda (K)

Eli Lilly Japan K.K, Kobe, Japan.

Alan J M Brnabic (AJM)

Eli Lilly Australia Pty. Limited, West Ryde, Australia.

Tamas Treuer (T)

Eli Lilly and Company, Budapest, Hungary, EU.

Masayo Sato (M)

Eli Lilly Japan K.K, Kobe, Japan.

Kristin Kahle-Wrobleski (K)

Eli Lilly and Company, Indianapolis, IN, USA.

Kenichi Meguro (K)

Geriatric Behavioral Neurology Project, New Industry Creation Hatchery Center (NICHe), Tohoku University, Sendai, Japan, Division of Nuclear Medicine, Cyclotron Radioisotope Center (CYRIC), Tohoku University, Sendai, Japan, and The Osaki-Tajiri SKIP Center, Osaki, Japan.

Masahito Yamada (M)

Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.

Masaru Mimura (M)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.

Heii Arai (H)

ALZCLINIC TOKYO, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH